Opus KSD discloses $680,801 equity sale to 16 investors in Form D filing
The Pembroke, Massachusetts biotechnology firm reported a completed Regulation D offering with a first sale date of September 23, 2026.
Opus KSD, Inc., a Delaware corporation based in Pembroke, Massachusetts, filed a Form D notice with the Securities and Exchange Commission describing an exempt securities offering. The company's principal place of business is listed at 50 Corporate Park Dr., Suite 710, Pembroke, Massachusetts 02359.1
The filing is a new notice, with a date of first sale listed as September 23, 2026.1 The offering involved equity securities.1 The company claimed the Rule 506(b) exemption under federal securities law.1
The total offering amount and the total amount sold were both reported at $680,801, with nothing remaining to be sold.1 The filing states that 16 investors have already put money into the offering.1 The minimum investment accepted from any outside investor was set at $10,000.1
The company reported no sales commissions or finders' fees in connection with the offering.1 It also reported no proceeds used for payments to executive officers, directors, or promoters named in the filing.1
The filing names six individuals as executive officers and directors: Charles Rogers, Saud Alturki, Porter Anderson, Kenneth Danielson, Christos Monovoukas, and Wei Shen, all listed at the same Pembroke address.1
Opus KSD identified its industry as biotechnology within the health care sector.1 The company selected "decline to disclose" for its issuer size, covering both revenue range and aggregate net asset value range.1
The notice was signed by Ryan L. Lolar, acting under power of attorney from Charles Rogers, CEO, and dated October 1, 2026.1 The company indicated it does not intend the offering to last more than one year.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.